Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Moderna CEO Stéphane Bancel
https://finance.yahoo.com/video/yahoo-finance-presents-moderna-ceo-190832537.html
And I expect Q4 to be even stronger than Q3. Because as you can imagine, in July, August, people are waiting for the new version. So I think it's going to be really kind of late August, September, and then massive ramp up to Q4.
Q4. As we've said, we're going to present data in cancer for the first time. And that's a personalized cancer product that is made differently for every human being based on the genetic signature of a cancer. And it's a big study. It's head to head with Keytruda, Merck's product, which as is the gold standard in terms of oncology.
The best thing about Moderna is that it is not just about Covid. Proven tech, an incredible pipeline with 4 other candidates in Phase 3 and with a PE ratio of 6 it should and will be trading closer to $500 than $200!!!!!!!!!!
Forest for the trees
One's opinion is honored
While the facts persist
Where does it go
From here
Sure feels good to see some great Revenues, Earnings and a new Buyback announced this morning.
Fantastic rally today. Sure glad I held all Shares thru the rough days that we've had since last Fall.
Time to get this moving back in the good ole days of Spring 2020 thru Spring 2021.
Let's go MRNA - Time to make some big $$$$ again.
Moderna is looking like a great investment again. PPS up 17% today, ready to reclaim 200 day ma. We aren’t hearing much from the guys claiming it was headed to “zero”, vaccinated individuals are not dropping dead as predicted, Bancel is not accused of any wrongdoing.
As the stock market comes out of the tragic Bear Market, MRNA will be a leader again. It has been a painful time but we’re making money again.
Company reiterates advance purchase agreements for expected delivery in 2022 of approximately $21 billion
Given our strong financial position and commercial momentum, we are announcing today that the Board of Directors has approved a new share repurchase program for $3 billion," said Stéphane Bancel, Chief Executive Officer of Moderna
PCV (mRNA-4157) Phase 1 ongoing; Phase 2 fully enrolled, data expected in 4Q 2022
https://www.cancer.gov/publications/dictionaries/cancer-drug/def/mrna-based-personalized-cancer-vaccine-mrna-4157
That will be interesting
Australia makes Covid vaccine Moderna available to vulnerable children from six months old
https://www.theguardian.com/australia-news/2022/aug/03/australia-makes-covid-vaccine-moderna-available-to-children-from-six-months-old
tomorrow :MODERNA TO REPORT SECOND QUARTER FINANCIAL RESULTS 8:00 a.m.
The ones that disappear are not vaccinated. Republicans in red states are antivaxers because t45 told them it was a fake hoax, then he got it, received a cocktail of drugs unavailable to anyone else and got vaccinated.
Curious how those who call themselves “conservatives” resist these conservative medical practices. Such a crazy switch inside their heads make them skeptical liberals of government control.
They never said 100% effective. No vaccine is.
Reduce hospitalization, yes, reduce death, yes.
That much has been accomplished.
Understanding evolution and how often small things like viruses and bacteria mutate, you might realize that methicillin resistant staph (Penicillin resistant) and methicillin pneumonia, evolved because of routine use of antibiotics in the food supply and in medicine.
Same with viruses, about every two weeks viruses mutate in many different directions. Some are unsuccessful, some or often one is most successful at being more contagious, but less deadly. This is a natural process, just like flu, and other viruses and bacteria.
What ever happened to 100% effective
Now they say
"we knew it was not going to work"
https://www.bitchute.com/video/0LleKAO15L0X/ (13:18)
Conclusion Booster vaccination with mRNA-1273 COVID-19 vaccine was more effective than BNT162b2 in preventing SARS-CoV-2 infection and COVID-19 hospitalisation during the first 12 weeks after vaccination.
https://www.medrxiv.org/content/10.1101/2022.07.29.22278186v1
Classic misinformation confusing “messenger RNA vaccines” with “gene therapy” aka DNA modification.
Might want to look up what the real difference is.
MRNA vs CRISPER
The messenger RNA has to be encapsulated in a lipid (fat molecule) or it will be destroyed by the body’s natural mRNA processes. At any given moment, 60 seconds pre minute, 60 minutes per hour, and 24 hours per day, approximately 5,000 messenger RNA’s are created by the body’s cells, read by other cells, proteins are encoded from the messenger RNA, and the messenger RNA is discarded like a Snapchat, disassembled to be reused in a different form again and again. This is normal and has nothing to do with the messenger RNA vaccine, which simply copies this normal cellular process which occurs in every animal, vaccinated or not.
The messenger RNA never enters the nucleus, where the DNA resides.
CRISPER is a gene splicing technique that does alter the DNA.
Don’t confuse the two.
Hopefully, you will read and comprehend this, but I’m fairly certain it won’t change your short position based on your confirmation bias and cognitive dissonance.
Once you've done it, you can't go back
https://www.bitchute.com/video/KGEgLwdDh5Hh/ (0:51)
Awesome Bro
MRNA $$$$
Moderna Announces New Supply Contract With the U.S. Government for an Initial 66M Doses of a Moderna Bivalent Covid-19 Booster!
New U.S. government contract includes an award up to $1.74 billion for 66 million doses to be delivered in 2022; additional options, if exercised, may raise total to 300 million doses
https://finance.yahoo.com/news/moderna-announces-supply-contract-u-120000075.html
Our Chief Medical Officer Paul Burton joins other leaders at the White House Summit on the Future of COVID-19 Vaccines to discuss next generation vaccine design and manufacturing, and efforts to accelerate the development & production of more broadly protective COVID19 vaccines.
HAPPENING NOW: Tune in here for the White House Summit on the Future of COVID-19 Vaccines, hosted by Dr. Ashish Jha and the White House COVID-19 Response Team. https://t.co/9jS5EdQKlP
— White House COVID-19 Response Team (@WHCOVIDResponse) July 26, 2022
Moderna expanding in 6 new countries in Europe as the world desperately awaits a new MRNA BA.5 vaccine.
US-based mRNA therapeutics and vaccines maker Moderna has announced its plans to expand its commercial network across six additional countries in Europe.
The biotech company is expected to establish its commercial presence in Belgium, Denmark, Norway, the Netherlands, Poland, and Sweden.
With the expanded footprint, the company aims to support the local delivery of mRNA vaccines and therapeutics in those regions.
The announcement follows Moderna’s recent plans establishing four new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong.
EMA COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) RECOMMENDS USE OF THE MODERNA COVID-19 BOOSTER IN ADOLESCENTS (12-17 YEARS) IN THE EUROPEAN UNION
https://investors.modernatx.com/news/news-details/2022/EMA-Committee-for-Medicinal-Products-for-Human-Use-CHMP-Recommends-Use-of-the-Moderna-COVID-19-Booster-in-Adolescents-12-17-Years-in-the-European-Union/default.aspx
$MRNA winner
Is It Too Late to Buy Moderna Stock:enjoy the reading
So, is it too late to buy Moderna shares? If you're looking for a quick gain, yes. But if you're looking for a company that will deliver over time, it's not too late to get in on Moderna shares. You can buy shares of the biotech for only five times forward earnings estimates. So, actually, if you buy now, your timing may be perfect.
https://www.fool.com/investing/2022/07/20/is-it-too-late-to-buy-moderna-stock/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
CAMBRIDGE, MA / ACCESSWIRE / July 18, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna's mRNA COVID-19 vaccine, Spikevax, in a two-dose series of 25 µg per dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6 months to 5 years. Until now, children under six were the only age group not eligible for vaccination against COVID-19 in Australia.
https://investors.modernatx.com/news/news-details/2022/Therapeutic-Goods-Administration-Grants-Provisional-Approval-for-Modernas-COVID-19-Vaccine-in-Children-Aged-Six-Months-to-Five-Years/default.aspx
- Canada on Thursday authorized Moderna Inc's COVID-19 vaccine for babies as young as 6 months old, making it the country's first vaccine against coronavirus for children under 5, Health Canada said.
Looking at the recent chart on MRNA: WOW. I do not buy calls on any stock during this type of bear market but I am tempted.
Moderna (MRNA) Gets a Buy Rating from Brookline Capital Markets
https://ih.advfn.com/stock-market/NASDAQ/moderna-MRNA/stock-news/88574757/moderna-mrna-gets-a-buy-rating-from-brookline-capi
MODERNA ANNOUNCES FIRST PARTICIPANT DOSED IN A PHASE 1 TRIAL OF ITS NIPAH VIRUS MRNA VACCINE, MRNA-1215
NiV is a zoonotic virus, meaning that it can spread between animals and people. The virus can be transmitted to humans from infected animals, through consumption of contaminated food, or directly from other infected persons. NiV is a deadly pathogen that can cause rapidly progressive illness, including acute respiratory infection and encephalitis that can lead to a coma or death. While it is possible to recover, an estimated 40% to 75% of people infected with NiV die as a result of infection.
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-First-Participant-Dosed-in-a-Phase-1-Trial-of-its-Nipah-Virus-mRNA-Vaccine-mRNA-1215/default.aspx
Moderna Best Performer in the Nasdaq 100 So Far Today -- Data Talk
Source: Dow Jones News
Moderna, Inc. (MRNA) is currently at $178.32, up $2.09 or 1.19%
--Would be highest close since March 29, 2022, when it closed at $180.64
--Currently up 14 of the past 15 days
--Currently up eight consecutive days; up 25.41% over this period
--On pace for its longest winning streak on record; The current record winning streak is the seven trading days ending Sept. 20, 2019 (Based on available data back to Dec. 7, 2018)
--Best eight day stretch since the eight days ending March 23, 2022, when it rose 29.33%
--Up 24.83% month-to-date
--Down 29.79% year-to-date
--Down 63.19% from its all-time closing high of $484.47 on Aug. 9, 2021
--Down 25.50% from 52 weeks ago (July 12, 2021), when it closed at $239.34
--Down 63.19% from its 52-week closing high of $484.47 on Aug. 9, 2021
--Up 52.24% from its 52-week closing low of $117.13 on June 13, 2022
--Traded as high as $180.48
--Up 2.41% at today's intraday high
--Fifth best performer in the S&P 500 today
--Best performer in the Nasdaq 100 today
All data as of 11:20:32 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
July 11, 2022 11:44 ET (15:44 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
MRNA $$$$
imo...
news: MODERNA'S OMICRON-CONTAINING BIVALENT BOOSTER CANDIDATE, MRNA-1273.214, DEMONSTRATES SIGNIFICANTLY HIGHER NEUTRALIZING ANTIBODY RESPONSE AGAINST OMICRON SUBVARIANTS BA.4/5 COMPARED TO CURRENTLY AUTHORIZED BOOSTER
https://investors.modernatx.com/news/news-details/2022/Modernas-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273.214-Demonstrates-Significantly-Higher-Neutralizing-Antibody-Response-Against-Omicron-Subvariants-BA.45-Compared-To-Currently-Authorized-Booster/default.aspx
$MRNA
Moderna’s Noubar Afeyan on the race to create a Covid vaccine
“We have 46 programmes and fortunately we now have the financial resources to prosecute them all.
“I can’t tell you which drugs in our mRNA platform are going to be approved first?.?.?.?but I’m very confident some of the 46 drug candidates in our pipeline will be successful.”
https://www.ft.com/content/39aac697-788b-4a2b-8b27-d6c865b736a9?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev
$MRNA
Still holding since Covid my ROTH IRA account is amazing
MRNA
Agree 100 % !
MRNA $$$$
Enjoy the weekend all !
Impressive climb... June 14th = Low $115.89 to present price.
Taiwan to receive 2nd-generation Moderna COVID vaccines in October. US expected to complete emergency use authorization process in late September or October.
Now MRNA has moved up 50% since the low of June 13. A powerful trend. Someone on this board predicted it would fall below $100 and also predicted Bancel would be tried and convicted of crimes against humanity and those of us who were vaccinated a year and a half ago would be dying.
The future is bright for Moderna and the stock is still cheap ( forward PE ratio of 6.17). Someone is screaming BUY.
Meet ‘Centaurus,’ the new ‘stealth Omicron.’ It was just found in the U.S. and may escape immunity more than any other COVID strain
https://finance.yahoo.com/news/meet-centaurus-stealth-omicron-just-185116816.html
WAS ONCE my best holding---like all of them they slid down before anyone noticed
Didn’t noticed that, thanks for sharing
Wow , awesome Bro !
MRNA $$$$
Free Float reduced to 295M shares ! This will fly so much !
Followers
|
176
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
13326
|
Created
|
12/10/18
|
Type
|
Free
|
Moderators DewDiligence Vexari axelvento |
2021 was a year of monumental impact and change for Moderna
Moderna entered 2021 with a strong cash position of approximately $5.25 billion. We have used this capital to invest in R&D and scale our development pipeline and manufacturing capabilities to maximize our impact on human health.
As we close our books for 2021, the company’s cash, cash equivalents and investments as of December 31, 2021, were more than $17 billion. We now have the resources to scale our investments and do even more to positively impact human health with mRNA medicines. This is just the beginning.
.
https://www.modernatx.com/newsroom/our-blog-coding-region/moderna-2021-shareholder-letter
Moderna is entering 2022 with a remarkable team poised to continue advancing mRNA vaccines and therapeutics into new areas for patients. We have a clear and exciting strategic path to do so, and a strong cash position.
Priority two is to go after the most important latent viruses and develop first-in-class vaccines against them. We want to protect our fellow human beings from suffering from the long-term damage caused by these viruses. Too many people have the quality of their health impacted because decades before, they were infected with a latent virus. We envision a world where vaccines against all the most important latent viruses are available to all.
Priority three is to bring to market therapeutics based on mRNA-encoded proteins, like our current pipeline in oncology, cardiology, rare genetic diseases and autoimmune diseases.
Priority four is to bring to market innovative therapeutics based on mRNA-encoded gene editing enzymes.
Moderna expects to enroll approximately 34,000 participants in multiple countries
RSV is a leading cause of severe respiratory illness in older adults (65+) and young children; there is no approved vaccine to prevent RSV
RSV illness in older adults results in an estimated $3 billion in annual medical costs in the U.S. each year
NOVEMBER, 18, 2021
https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-First-Participant-Dosed-in-Phase-2-3-Study-of-its-mRNA-Respiratory-Syncytial-Virus-RSV-Vaccine/default.aspx
MODERNA ANNOUNCES POSITIVE DATA FROM PHASE 2 STUDY OF MRNA VEGF-A THERAPEUTIC IN PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING SURGERY
Approval based on a comprehensive submission package including efficacy and safety data approximately six months after second dose
SPIKEVAX has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
807 million doses of Moderna's COVID-19 vaccine shipped globally in 2021; approximately 25% of those doses shipped to low- and middle-income countries
https://investors.modernatx.com/news/news-details/2022/Moderna-Receives-Full-U.S.-FDA-Approval-for-COVID-19-Vaccine-Spikevax/default.aspx
Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29
Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of $28.29
Moderna increased its 2022 signed advance purchase agreements to approximately $19 billion, with additional signed options of approximately $3 billion; numerous discussions ongoing with governments for the fall of 2022 and 2023
Moderna received full U.S. FDA approval for COVID-19 vaccine, Spikevax
Moderna announces new bivalent booster candidate (mRNA-1273.214) combining Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273)
Company now has 44 programs in development
Moderna announces a new $3 billion share repurchase plan
https://investors.modernatx.com/news/news-details/2022/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2021-Financial-Results-and-Provides-Business-Updates/default.aspx
Facility to manufacture drug substance with opportunity for fill/finish and packaging capabilities
Moderna investing up to $500 million to produce up to 500 million doses each year for the African continent
Moderna will invest in building mRNA capabilities in Africa
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Memorandum-of-Understanding-with-the-Government-of-the-Republic-of-Kenya-to-Establish-its-First-mRNA-Manufacturing-Facility-in-Africa/default.aspx
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |